ArticlePloS one2016
Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Estimating the burden of antimicrobial resistance: a systematic literature review.Antimicrobial resistance and infection control · 2018Pooled it
- Increasing community vulnerability to gastrointestinal infections in austerity's shadow: a comparative study of two English local authorities.BMC public health · 2026Article
- Antimicrobial and anti-inflammatory properties ofMicrobiology (Reading, England) · 2026Article
- Enhanced laboratory surveillance study ofJournal of medical microbiology · 2025Article
- Article
- Evaluation of a FlpA Glycoconjugate Vaccine with TenVaccines · 2024Article
- A mathematical, classical stratification modeling approach to disentangling the impact of weather on infectious diseases: A case study using spatio-temporally disaggregated Campylobacter surveillance data for England and Wales.PLoS computational biology · 2024Article
- An ecological study of the spatiotemporal dynamics and drivers of domestically acquired campylobacteriosis in Ireland, 2011-2018.PloS one · 2023Article
- Emerging patterns of fluoroquinolone resistance inMicrobial genomics · 2022Article
- Can cases and outbreaks of norovirus in children provide an early warning of seasonal norovirus infection: an analysis of nine seasons of surveillance data in England UK.BMC public health · 2022Article
- Mechanisms of biodiversity betweenEcology and evolution · 2022Article
- School Attendance Registers for the Syndromic Surveillance of Infectious Intestinal Disease in UK Children: Protocol for a Retrospective Analysis.JMIR research protocols · 2022Article
- Article
- Can good broiler flock welfare prevent colonization by Campylobacter?Poultry science · 2021Article
- Understanding norovirus reporting patterns in England: a mixed model approach.BMC public health · 2021Article
- Transcriptomic analysis of caecal tissue in inbred chicken lines that exhibit heritable differences in resistance to Campylobacter jejuni.BMC genomics · 2021Article
- Using next-generation sequencing to develop a Shigella species threshold and profile faecal samples from suspected diarrhoea cases.Folia microbiologica · 2021Article
- Impact of self-financed rotavirus vaccination on acute gastroenteritis in young children in Turkey.Human vaccines & immunotherapeutics · 2021Article
- Quantitative trait loci and transcriptome signatures associated with avian heritable resistance to Campylobacter.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectivesTo estimate the annual cost to patients, the health service and society of infectious intestinal disease (IID) from Campylobacter, norovirus and rotavirus.
designSecondary data analysis.
settingThe United Kingdom population, 2008-9.
main outcome measuresCases and frequency of health services usage due to these three pathogens; associated healthcare costs; direct, out-of-pocket expenses; indirect costs to patients and caregivers.
resultsThe median estimated costs to patients and the health service at 2008-9 prices were: Campylobacter £50 million (95% CI: £33m-£75m), norovirus £81 million (95% CI: £63m-£106m), rotavirus £25m (95% CI: £18m-£35m). The costs per case were approximately £30 for norovirus and rotavirus, and £85 for Campylobacter. This was mostly borne by patients and caregivers through lost income or out-of-pocket expenditure. The cost of Campylobacter-related Guillain-Barré syndrome hospitalisation was £1.26 million (95% CI: £0.4m-£4.2m).
conclusionsNorovirus causes greater economic burden than Campylobacter and rotavirus combined. Efforts to control IID must prioritise norovirus. For Campylobacter, estimated costs should be considered in the context of expenditure to control this pathogen in agriculture, food production and retail. Our estimates, prior to routine rotavirus immunisation in the UK, provide a baseline vaccine cost-effectiveness analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.